CEL-SCI (CVM) Collaborators Present Data Suggesting That LEAPS Technology Has Ability to Modify Immune Response
11/9/2009 9:26:57 AM
More...
|
Completion of CEL-SCI (CVM)'s New Facility Signals That Long Awaited Phase III Trial is Imminent
10/26/2009 9:14:08 AM
More...
|
CEL-SCI (CVM) Presents Data at American College of Rheumatology Conference
10/19/2009 9:32:28 AM
More...
|
CEL-SCI (CVM) Releases Letter to Shareholders
10/6/2009 9:00:33 AM
More...
|
CEL-SCI (CVM) Announces Elimination of $8.3 Million Convertible Notes Company Continues to Strengthen Balance Sheet
9/3/2009 8:45:34 AM
More...
|
CEL-SCI (CVM) Signs Definitive Agreement to Raise $4.4 Million in Registered Direct Offering
8/20/2009 7:53:43 AM
More...
|
Biotech Drug Company CEL-SCI (CVM) Preparing for Worst Case H1N1 Flu Scenario Using Extremely Promising New Technology (NYSE Amex: CVM)
7/31/2009 10:16:40 AM
More...
|
CEL-SCI (CVM) to Present Data from Multikine Clinical Trials at National Institutes of Health (NIH), National Cancer Institute Seminar Series
7/10/2009 8:03:40 AM
More...
|
CEL-SCI (CVM) Releases Letter to Shareholders
7/8/2009 10:17:34 AM
More...
|
CEL-SCI (CVM) Completes $5.85 Million Registered Direct Offering
6/30/2009 12:05:13 PM
More...
|
|